Caspofungin and liposomal amphotericin B therapy of experimental murine scedosporiosis.
Immunosuppressed mice were infected intravenously with conidia of Scedosporium prolificans. Treatment was begun 1 day later with liposomal amphotericin B, caspofungin, or both drugs initiated concurrently. Amphotericin B and caspofungin were each effective, but combined therapy did not appear to offer advantages over liposomal amphotericin B alone.
Bocanegra
Rosie
R
The University of Texas Health Science Center at San Antonio, Department of Medicine/Division of Infectious Diseases (MC 7881), 7703 Floyd Curl Drive, San Antonio, Texas 78229-3900, USA. Bocanegra@uthscsa.edu
Najvar
Laura K
LK
Hernandez
Steve
S
McCarthy
Dora I
DI
Graybill
John R
JR
D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000077336:Caspofungin; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D054714:Echinocandins; D055666:Lipopeptides; D051379:Mice; D008271:Mycetoma / Q000188:drug therapy*; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D021681:Scedosporium
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D010456:Peptides, Cyclic; C068538:liposomal amphotericin B; D000666:Amphotericin B; D000077336:Caspofungin